The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker Novo Nordisk, confirmed that supply now meets or exceeds both the current ...

The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

The FDA declared the end of the shortage of Novo Nordisk’s Wegovy and Ozempic, impacting compounding pharmacies selling ...

In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., ...

The U.S. FDA has officially declared that Novo Nordisk’s (NVO) popular diabetes and weight loss therapies, Ozempic and Wegovy, are no longer in ...

But 25-year-old Madison Burgess has thrown caution to the wind by opting to micro-dose the drug. The Michigan native revealed ...

The U.S. Food and Drug Administration declared that the shortage of Novo Nordisk's weight-loss medications Wegovy and Ozempic has been resolved, according to its website. The FDA announcement confirms ...

The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs ...

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

Though more research is needed to understand who might benefit from GLP-1 agonists for addiction, early studies suggest that the approach holds promise.